Outcome of follicular lymphoma grade 3: is anthracycline necessary as front-line therapy?

被引:0
作者
I Chau
R Jones
D Cunningham
A Wotherspoon
N Maisey
A R Norman
P Jain
L Bishop
A Horwich
D Catovsky
机构
[1] Royal Marsden Hospital,Department of Medicine
[2] Royal Marsden Hospital,Department of Histopathology
[3] Royal Marsden Hospital,Department of Computing
[4] Royal Marsden Hospital,Academic Department of Haematology
[5] Royal Marsden Hospital,Department of Academic Radiotherapy
来源
British Journal of Cancer | 2003年 / 89卷
关键词
follicular lymphoma; WHO classification; cytological grading; anthracycline;
D O I
暂无
中图分类号
学科分类号
摘要
A grading system (grades 1–3) for follicular lymphoma (FL) is used in the WHO classification for lymphoid malignancies based on the absolute number of centroblasts in the neoplastic follicles. Grade 3 FL is further subdivided into 3a and 3b depending on the presence or absence of centrocytes. A total of 231 patients with FL, referred from 1970 to 2001, were identified from our prospectively maintained database. Original diagnostic materials were available for review on 215 patients and these were reclassified according to the WHO grading system. Follicular lymphoma grades 1, 2 and 3 accounted for 92, 68 and 55 patients, respectively. No significant overall survival (OS) differences were observed among FL grades 1–3 (log rank P=0.25) or between grades 3a and 3b (log rank P=0.20). No significant failure-free survival (FFS) differences were observed among FL grades 1–3 (log rank P=0.72) or between grades 3a and 3b (log rank P=0.11). First-line anthracyclines did not influence OS or FFS (log rank P=0.86, P=0.58, respectively) in patients with FL grade 3. There are long-term survivors among patients with FL grade 3 with a continuing risk of relapse. Anthracyclines did not appear to influence survival or disease relapses when given as front-line therapy in our series. The role of anthracyclines should be further evaluated in large randomised studies.
引用
收藏
页码:36 / 42
页数:6
相关论文
共 125 条
[1]  
Anderson JR(1993)Clinical features and prognosis of follicular large-cell lymphoma: a report from the Nebraska Lymphoma Study Group J Clin Oncol 11 218-224
[2]  
Vose JM(1998)New approach to classifying non-Hodgkin's lymphomas: clinical features of the major histologic subtypes. Non-Hodgkin's Lymphoma Classification Project J Clin Oncol 16 2780-2795
[3]  
Bierman PJ(1994)Follicular large-cell lymphoma: intermediate or low grade? J Clin Oncol 12 1349-1357
[4]  
Weisenberger DD(2002)CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma N Engl J Med 346 235-242
[5]  
Sanger WG(1994)A revised European–American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group Blood 84 1361-1392
[6]  
Pierson J(1958)Non parametric estimation from incomplete observations J Am Statist Assoc 53 457-481
[7]  
Bast M(1983)Criteria for the cytologic subclassification of follicular lymphomas: a proposed alternative method Hematol Oncol 1 187-192
[8]  
Armitage JO(1995)Prognostic value of cellular proliferation and histologic grade in follicular lymphoma Blood 85 3671-3678
[9]  
Armitage JO(1998)Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program J Clin Oncol 16 2825-2833
[10]  
Weisenburger DD(1997)Follicular lymphomas: do histologic subtypes predict outcome? Hematol Oncol Clin N Am 11 893-900